ClinicalTrials.gg
RecruitingNCT07319598Updated Jan 6, 2026

A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease

A Phase 4 interventional study of Tetrandrine Tablets and Placebo in Interstitial Lung Disease (ILD) and Connective Tissue Disease-associated Interstitial Lung Disease, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Peking University Third Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Nov 2023, registered Aug 2025).
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 76 studies in Lung Diseases, Interstitial with a site in China — 32 open to participants now, 38 under way, 9 of them phase 3. Lung Diseases, Interstitial · China.

Planned enrollment
27th of 53
100 · median 100
Started
2023
with 12 others
Phase 4
8 of 76
4 open now
Primary completion
2026-10
later than 10 of 37 live
Registered
64th of 76
by date

Among the 76 studies in Lung Diseases, Interstitial with a site in China, this one is the 27th largest by planned enrollment of the 53 interventional ones that give a count, is one of 13 that started in 2023, is one of 8 in phase 4, reaches primary completion later than 10 of the 37 other live ones, and was the 64th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

32 of the 76 studies in Lung Diseases, Interstitial with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Lung Diseases, Interstitial with a site in China, or all of them as a file.
02

Study summary

This study evaluates the efficacy and safety of tetrandrine tablets (60 mg, three times daily) compared to placebo in adult patients with connective tissue disease-related interstitial lung disease. Patients receive standard treatment (glucocorticoids and immunosuppressants) alongside the study drug or placebo for 24 weeks. The study measures changes in lung function, inflammatory markers, lung imaging, quality of life, and safety outcomes.

Read the detailed description

This multicenter, randomized, double-blind, placebo-controlled study enrolls 100 adults with connective tissue disease-related interstitial lung disease. Patients are randomized 1:1 to receive tetrandrine tablets (60 mg TID) or placebo for 24 weeks, alongside standard treatment. The primary outcome is the change in forced vital capacity (FVC) at 24 weeks. Secondary outcomes include changes in serum inflammatory markers (TGF-β1, KL6, TNF-α, IL-6), lung HRCT scores, other Lung function parameters (TLC, VC, DLCO, PaO2), St. George's Respiratory Questionnaire (SGRQ) score, safety parameters, and all-cause mortality. Visits occur at weeks 4, 8, 12, and 24 for efficacy and safety assessments.

03

Conditions studied

  • Interstitial Lung Disease (ILD)
  • Connective Tissue Disease-associated Interstitial Lung Disease

Keywords

  • Tetrandrine
  • Connective Tissue Disease
  • Interstitial Lung Disease
  • Pulmonary Function
  • Inflammatory Markers
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who voluntarily participate and sign the form
  • Male or female patients aged 18-80 years (inclusive)
  • Patients meeting the diagnostic criteria for connective tissue disease-related interstitial lung disease per the 2018 Chinese Expert Consensus at screening
  • FVC ≥40% of predicted value at screening
  • Fertile male or female patients must agree to use effective from signing informed consent until 3 months after the last study drug dose (Exemptions: women >50 years with amenorrhea for >1 year, or surgically sterilized women)
  • Patients on stable doses of prednisone (≤20 mg/day or equivalent) or for at least 4 weeks prior to study entry, with dose adjustments not exceeding this during the double-blind period

Exclusion criteria

Exclusion Criteria:

  • Treatment with tetrandrine or other antifibrotic drugs within 1 month before screening
  • Diabetes with fasting blood glucose greater than 11.1 mmol per L
  • Resting arterial oxygen partial pressure less than 50 mmHg
  • Active peptic ulcers or bleeding disorders
  • Tumors with expected survival less than 1 year
  • Active pulmonary tuberculosis
  • (ALT) or aspartate aminotransferase (AST) 5 times the (ULN) or higher, or ALT or AST 3 times ULN or higher with total 2 times ULN or higher
  • less than 30 mL per min (per Cockcroft-Gault formula) or patients receiving dialysis
  • Known allergy to tetrandrine or its
  • Severe psychological, mental, cognitive, or intellectual impairments that may affect compliance
  • Pregnant or breastfeeding women, or those planning pregnancy within 3 months after the last study drug dose
  • Participation in another clinical trial within 3 months before screening
  • Patients deemed unsuitable for the study by the investigator
  • environmental exposure history that may cause pulmonary fibrosis (e.g., amiodarone, asbestos, beryllium, radiation)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Tetrandrine Group

    Participants receive tetrandrine tablets (60 mg, three times daily) for 24 weeks, along with standard treatment (glucocorticoids and immunosuppressants).

    Drug: Tetrandrine Tablets

  • Placebo comparator
    Placebo Group

    Participants receive placebo tablets (mimicking tetrandrine, three times daily) for 24 weeks, along with standard treatment (glucocorticoids and immunosuppressants).

    Drug: Placebo

Interventions

  • DrugTetrandrineStudies of TetrandrineTetrandrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    60 mg (3 tablets, 20 mg each), orally three times daily (TID) for 24 weeks, with glucocorticoids and immunosuppressants

  • DrugPlacebo

    Placebo tablets mimicking tetrandrine, 3 tablets TID, orally for 24 weeks, with glucocorticoids and immunosuppressants

06

What researchers measure

Primary outcomes

  1. Change in Forced Vital Capacity (FVC)

    Change in forced vital capacity (FVC) expressed in liters (L) of predicted normal value, measured using a pulmonary function testing device in accordance with ATS/ERS standards at a central facility. Units: Absolute value(L)

    Time frame: Baseline to 24 weeks

Secondary outcomes

  1. Change in Serum Transforming Growth Factor Beta 1 (TGF-β1) Level

    Serum TGF-β1 levels measured via fully automated analyzer. Units: ng/mL

    Time frame: Baseline to 24 weeks

  2. Change in Serum Krebs von den Lungen-6 (KL6) Level

    Serum KL6 levels measured via fully automated analyzer. Units: U/mL

    Time frame: Baseline to 24 weeks

  3. Change in Serum Tumor Necrosis Factor Alpha (TNF-α) Level

    Serum TNF-α levels measured via fully automated analyzer. Units: pg/mL

    Time frame: Baseline to 24 weeks

  4. Change in Serum Interleukin-6 (IL-6) Level

    Serum IL-6 levels measured via fully automated analyzer. Units: pg/mL

    Time frame: Baseline to 24 weeks

  5. Change in Semi-Quantitative High-Resolution Computed Tomography (HRCT) Score

    Semi-quantitative scoring of HRCT patterns (reticulation, ground-glass opacity, patchy/consolidation, honeycombing) across 6 predefined lung layers. Each pattern scored 0 (absent) to 4 (\>75% involvement); total score summed (maximum 96). Higher scores indicate worse outcome (greater lung involvement). Units: Score (0-96)

    Time frame: Baseline to 24 weeks

  6. Change in Total Lung Capacity (TLC)

    TLC measured via body plethysmography (ATS/ERS standards) at central facility. Units: Absolute value(L)

    Time frame: Baseline to 24 weeks

  7. Change in Vital Capacity (VC)

    VC measured via spirometry (ATS/ERS standards) at central facility. Units: Absolute value(L)

    Time frame: Baseline to 24 weeks

  8. Change in Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)

    Single-breath DLCO (hemoglobin-corrected) measured via ATS/ERS standards at central facility.

    Time frame: Units: Absolute value(L)

  9. Change in Arterial Partial Pressure of Oxygen (PaO2)

    PaO2 from arterial blood gas (at rest, room air). Units: mmHg

    Time frame: Baseline to 24 weeks

  10. Change in St. George's Respiratory Questionnaire (SGRQ) Total Score

    Change in total score from Chinese-validated SGRQ (self-administered, 3-month recall), assessing respiratory health-related quality of life across Symptoms, Activity, and Impacts domains (weighted). Scores range from 0 (no impairment/best quality of life) to 100 (maximum impairment/worst quality of life). Higher scores indicate worse outcome. Units: Score (0-100)

    Time frame: Baseline to 24 weeks

  11. Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    Incidence of treatment-related adverse events (any untoward event post-randomization), graded by CTCAE v5.0 (coded via MedDRA). Includes abnormalities in hematology, chemistry, urinalysis, liver/kidney function. Units: Number of cases

    Time frame: Baseline to 24 weeks

  12. Number of Participants with Treatment-Emergent Serious Adverse Events

    Incidence of serious adverse events as assessed by CTCAE v5.0. Units: Number of cases

    Time frame: Baseline to 24 weeks

  13. Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECG)

    Incidence of clinically significant ECG abnormalities (e.g., QTc prolongation) from 12-lead ECGs. Units: Number of cases

    Time frame: Baseline to 24 weeks

  14. Number of Participants with All-Cause Mortality

    Number and percentage of participants who died from any cause during the study period (all-cause mortality), ascertained via follow-up and vital status checks. Units: Number of cases

    Time frame: Baseline to 24 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Oct 2026, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Jan 6, 2026
StartActual
Nov 2, 2023
Primary completionEst.
Oct 15, 2026
CompletionEst.
Jan 1, 2027
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07319598
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Nov 2, 2023
Primary completion
Oct 15, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Jan 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tetrandrine

Start the discussion